Waters Corporation
WATWaters sells mission-critical analytical instruments that become deeply embedded in pharmaceutical and research workflows.
Because the real story is whether this steady, profitable lab franchise can compound meaningfully over the next two decades.
Business Model
Devices plus services
It sells complex lab instruments and then earns recurring revenue from service, parts, and consumables.
Economic Engine
High cash generation
Gross margins near 58% and operating margins above 28% turn sales into real profits.
Long-Term Lens
Ecosystem durability
The key question is whether its instruments stay embedded in labs as science and technology evolve.
On this page
Company Story
How do Waters Corporation's business model and economics hold up on a closer read?
Start with the business itself, then go one layer deeper into the model, the economics, and the long-term case.
“A high-margin lab equipment franchise with sticky customers, but long-term upside depends on reigniting durable growth.”
What does Waters Corporation actually do?
Waters Corporation designs and sells high-end laboratory instruments that analyze chemicals and biological samples.
- Builds liquid chromatography and mass spectrometry systems used in drug development
- Sells testing tools to pharmaceutical, biotech, food, and environmental labs
- Provides ongoing service, software, and replacement parts
Why it matters
Mission-critical science tools
Drug makers and research labs rely on these machines for regulatory approval and quality control, which makes them hard to rip out once installed.
How does Waters Corporation make money?
Waters makes money by selling expensive instruments upfront and then generating steady revenue from servicing and supporting them.
- Initial sale of analytical instruments
- Recurring service contracts and maintenance
- Replacement parts, consumables, and software
Economic clue
High margin profile
A gross margin of 57.8% and operating margin of 28.2% show pricing power and recurring economics.
Why do long-term investors keep Waters Corporation on the radar?
Waters sits at the center of global drug research and testing, industries that are likely to expand over decades.
- Aging populations drive long-term demand for new medicines
- Regulatory requirements increase testing and quality standards
- Installed instruments create long customer relationships
Investor takeaway
Durable but slow compounding
Revenue has grown about 3.2% per year on average over five years, suggesting steady but not explosive expansion.
Based on company financial statements.
Benchmark Comparison
How has Waters Corporation performed against common long-term benchmarks?
Once the business case is clear, compare the stock against broad market and alternative long-term baselines.
$1,135
+13.5% total return
$1,753
+75.3% total return
$2,975
+197.5% total return
$1,393
+39.3% total return
| Asset | Total Return | Dollar Value |
|---|---|---|
| WAT | +13.5% | $1,135 |
| S&P 500 | +75.3% | $1,753 |
| Gold | +197.5% | $2,975 |
| Bitcoin | +39.3% | $1,393 |
From Mar 5, 2021 to Mar 6, 2026. Historical price data based on company financial statements and market indices. Each card uses the same starting amount so the comparison stays apples-to-apples.
Investor Fit
How a first-time investor could frame Waters Corporation
Before going deeper, decide what kind of business this is, what it tends to suit, and what deserves monitoring over time.
This Can Fit If You Want
- Exposure to long-term pharmaceutical and biotech research growth
- A profitable business with a 20.3% net margin
- A company that generates solid free cash flow from installed equipment
Be Careful If You Expect
- Rapid double-digit revenue growth year after year
- Rising margins, since margins have been contracting recently
- A dividend stream, since the company pays none
What To Watch Over Time
- Whether average annual revenue growth rises above the recent 3.2% pace
- Whether operating margin stabilizes above 28% or keeps slipping
- The balance between new instrument sales and recurring service revenue
Key Metrics
Which metrics matter most for Waters Corporation right now?
Three durable business metrics that matter more than day-to-day price moves.
3.2% per year
-1.0% per year
57.8% gross margin
| Metric | Value | Context |
|---|---|---|
| Revenue Growth | 3.2% per year | Shows whether the business has been expanding fast enough to create more long-term value. |
| EPS Growth | -1.0% per year | Shows whether earnings per share are compounding for owners over time. |
| Margin Quality | 57.8% gross margin | Shows how much room the business has to fund growth, absorb shocks, and stay profitable. |
Based on company financial statements.
Fundamentals
What do Waters Corporation's fundamentals say right now?
Core financial markers that explain how the business is performing beneath the stock price.
27.8% ROIC
57.8% gross margin
17.1% FCF margin
Stable to shrinking
| Metric | Value | Interpretation |
|---|---|---|
| Capital Efficiency | 27.8% ROIC | The business is currently showing excellent capital efficiency. |
| Profitability | 57.8% gross margin | Healthy gross margins give the company room to invest, price competitively, and absorb shocks. |
| Cash Generation | 17.1% FCF margin | Free cash flow margin shows how much real cash the business keeps after funding operations and investment. |
| Ownership Trend | Stable to shrinking | The company is not currently diluting owners and may be buying back shares instead. |
Based on company financial statements.
Included In Funds
Which ETFs and funds currently hold Waters Corporation?
Waters Corporation currently appears in these ETF and fund proxies.
SPY
SPDR S&P 500 ETF Trust
IWB
iShares Russell 1000 ETF
Questions & Answers
What questions come up most often about Waters Corporation?
Company-specific questions readers often ask about Waters Corporation.
Each entry answers a direct question about the business, the long-term thesis, or the risks that matter over time.
Waters Corporation builds laboratory instruments that analyze chemicals and biological samples for pharmaceutical, biotech, food, and environmental labs.
Decision Framing
Secondary context after the long-term thesis
Shorter-horizon context and comparison tools, after the core long-term read.
Shorter-horizon price moves, two-sided debate, and comparison tools live here so the page stays anchored on business quality, durability, and BinaPrint fit first.
Investment Thesis
Bull vs Bear
Two-sided framing before any decision.
Current argument weight is balanced.
Bull case
What can work
Installed instruments become embedded in pharmaceutical workflows, creating switching costs because labs must revalidate processes if they change systems.
Aging populations and rising chronic disease rates drive sustained demand for new drugs, increasing long-term need for analytical testing.
High gross margins of 57.8% provide room to invest in research and maintain technological leadership over smaller competitors.
Recurring service and consumables revenue smooths results and supports durable cash generation over economic cycles.
Bear case
What can break
Breakthrough analytical technologies could make traditional chromatography systems less relevant, eroding the core franchise over 10 to 20 years.
Large customers such as global pharmaceutical companies could consolidate vendors and pressure pricing, squeezing margins below the current 28.2% operating level.
If drug research spending slows structurally due to regulation or political pressure on drug pricing, demand for new instruments could stagnate.
Competitors with deeper pockets could outspend Waters on research, gradually taking share in next-generation platforms.
Risk Radar
Key Risks
Where downside pressure can build.
Margin erosion, with operating margin at 28.2% and trending downward, could reduce long-term earnings power if it falls several percentage points.
Growth stagnation, with five-year average revenue growth of 3.2% and earnings per share shrinking 1.0% per year on average.
Customer concentration in pharmaceutical and biotech sectors, which are sensitive to research funding cycles.
Sizing matters
Risks should be read as scenario inputs, not certainties. Position size and time horizon determine how much of this downside profile is acceptable.
Market Snapshot
Tactical context after the core long-term read.
- Price
- $302.54
- Daily move
- -4.14%
Peer Set
A compact peer list for side-by-side context.
Next Actions
Explore planning scenarios or keep browsing similar companies.